Among these agents, low-dose topotecan (TPT) can induce “favorable” SASP and activate antitumor immune responses; in contrast, bromodeoxyuridine-induced SASP secretion by neuroblastoma cells can promote tumor progression in an NFKB1/p50-dependent manner. The gene discussed is NFKB1; the disease is neoplasm.